Advertisement
UK markets closed
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • CRUDE OIL

    83.10
    +1.75 (+2.15%)
     
  • GOLD FUTURES

    2,240.20
    +27.50 (+1.24%)
     
  • DOW

    39,772.20
    +12.12 (+0.03%)
     
  • Bitcoin GBP

    55,890.84
    +1,437.18 (+2.64%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    16,379.90
    -19.62 (-0.12%)
     
  • UK FTSE All Share

    4,338.05
    +12.12 (+0.28%)
     

MicroVision Announces Fourth Quarter and Full Year 2022 Results

MicroVision, Inc.

REDMOND, WA / ACCESSWIRE / February 28, 2023 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced its fourth quarter and full year 2022 results.

"2022 was a transformational year for MicroVision. We announced the joining of forces with Ibeo Automotive which closed in January 2023 and uniquely positions us in the market." said Sumit Sharma, MicroVision's Chief Executive Officer. "Our expanded product portfolio now includes the dynamic view MEMS-based scanning lidar for long-range highway pilot, flash-based short-range lidar for automotive and non-automotive applications, and a validation software suite for OEMs and Tier 1s."

Buoyed by actions taken in the fourth quarter, the Company is now the only lidar company in the market able to offer hardware and software solutions ready to deliver to the ADAS market; sensors for non-automotive markets including industrial, robotics, and smart infrastructure; and a software suite for automotive customers in their ADAS validation work.

"MicroVision continues to strategically deploy capital, emerging as one of the strongest lidar companies on the market," continued Sharma. "I am pleased with how quickly our engineering teams from the U.S. and Germany came together to integrate MAVIN TM DR with mature perception software. This early demonstration of synergies, combining MAVIN with perception, advances our positioning in existing RFIs and RFQs as well as others that are expected this year and beyond from several OEMs across the globe. We expect to accelerate our 2023 revenue in the range of $10-15 million from our expanded product suite. Our very competitive cost structure combined with our superior design and technology positions us well relative to our peers."

ADVERTISEMENT

Key Financial Highlights for Q4 and Full Year 2022

  • Revenue for the fourth quarter of 2022 was $0, compared to $0.6 million for the fourth quarter of 2021. As stated in prior quarters, the revenue was recognized against cash that had been received in an earlier period.

  • Net loss for the fourth quarter of 2022 was $13.5 million, or $0.08 per share, which includes $3.5 million of non-cash, share-based compensation expense, compared to a net loss of $12.6 million, or $0.08 per share, which includes $2.9 million of non-cash, share-based compensation expense, for the fourth quarter of 2021.

  • Adjusted EBITDA for the fourth quarter of 2022 was a $9.7 million loss, compared to a $9.3 million loss for the fourth quarter of 2021.

  • Cash used in operations in the fourth quarter of 2022 remained flat at $8.4 million, compared to cash used in operations in the fourth quarter of 2021 of $8.2 million.

  • The Company ended the fourth quarter of 2022 with $82.7 million in cash and cash equivalents including investment securities, compared to $115.4 million at December 31, 2021.

Conference Call and Webcast: Q4 and Full Year 2022 Results

MicroVision will host a conference call and webcast, consisting of prepared remarks by management, a slide presentation, and a question-and-answer session at 2:00 PM PT/5:00 PM ET on Tuesday, February 28, 2023 to discuss the financial results and provide a business update. Analysts and investors may pose questions to management during the live webcast on February 28, 2023.

The live webcast and slide presentation can be accessed on the Company's Investor Relations website under the Events tab at https://ir.microvision.com/events . The webcast will be archived on the website for future viewing.

About MicroVision

With over 350 employees and offices in Redmond, Detroit, Hamburg, and Nürnberg, MicroVision is a pioneering company in MEMS-based laser beam scanning technology that integrates MEMS, lasers, optics, hardware, algorithms and machine learning software into its proprietary technology to address existing and emerging markets. The Company's integrated approach uses its proprietary technology today to develop automotive lidar sensors and provide solutions for advanced driver-assistance systems (ADAS), leveraging its experience building augmented reality micro-display engines, interactive display modules, and consumer lidar modules.

For more information, visit the Company's website at www.microvision.com , on Facebook at www.facebook.com/microvisioninc , follow MicroVision on Twitter at @MicroVision , and LinkedIn at https://www.linkedin.com/company/microvision/ .

MicroVision and MAVIN are trademarks of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.

Non-GAAP information

To supplement MicroVision's condensed financial statements presented in accordance with GAAP, the Company presents investors with the non-GAAP financial measure "adjusted EBITDA." Adjusted EBITDA consists of GAAP net income (loss) excluding the impact of the following: interest income and interest expense; income tax expense; depreciation and amortization; and share-based compensation.

MicroVision believes that the presentation of adjusted EBITDA provides important supplemental information to management and investors regarding financial and business trends, provides consistency and comparability with MicroVision's past financial reports, and facilitates comparisons with other companies in the Company's industry, many of which use similar non-GAAP financial measures to supplement their GAAP results. Internally, management uses this non-GAAP measure when evaluating operating performance because the exclusion of the items described above provides an additional useful measure of the Company's operating results and facilitates comparisons of the Company's core operating performance against prior periods and its business objectives. Externally, the Company believes that adjusted EBITDA is useful to investors in their assessment of MicroVision's operating performance and the valuation of the Company.

Adjusted EBITDA is not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the costs associated with the operations of MicroVision's business as determined in accordance with GAAP. The Company expects to continue to incur expenses similar to the non-GAAP adjustments described above, and exclusion of these items from its non-GAAP financial measure should not be construed as an inference that these costs are unusual or infrequent. The Company compensates for limitations of the measure by prominently disclosing GAAP net income (loss), which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation from GAAP net income (loss) to adjusted EBITDA.

MicroVision has included a reconciliation of GAAP net income (loss) to adjusted EBITDA for the relevant periods.

Forward-Looking Statements

Certain statements contained in this release, including the Company's plans regarding benefits of the acquisition, market position, product portfolio, product capabilities, and expected revenue, expenses and cash usage are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in such forward-looking statements include the risk its ability to operate with limited cash or to raise additional capital when needed; market acceptance of its technologies and products or for products incorporating its technologies; the failure of its commercial partners to perform as expected under its agreements, including from the impact of COVID-19 (coronavirus); its financial and technical resources relative to those of its competitors; its ability to keep up with rapid technological change; government regulation of its technologies; its ability to enforce its intellectual property rights and protect its proprietary technologies; the ability to obtain customers and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market its products; potential product liability claims; its ability to maintain its listing on The Nasdaq Stock Market, and other risk factors identified from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect the Company. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect the Company to a greater extent than indicated. Except as expressly required by federal securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.

MicroVision, Inc.
Consolidated Balance Sheet
(In thousands)
(Unaudited)


December 31,

December 31,

2022

2021

Assets

Current Assets



Cash and cash equivalents

$

20,536

$

82,647

Investment securities, available-for-sale

62,173

32,720

Inventory

1,861

1,780

Advance to IBEO

4,132

-

Other current assets

2,306

2,283

Total current assets

91,008

119,430


Property and equipment, net

6,830

3,026

Operating lease right-of-use asset

14,579

5,577

Restricted cash

1,418

1,092

Intangible assets, net

75

115

Other assets

1,086

985

Total assets

$

114,996

$

130,225

Liabilities and Shareholders' Equity

Current Liabilities

Accounts payable

$

2,061

$

3,584

Accrued liabilities

2,058

1,170

Contract liabilities

4,601

5,265

Other current liabilities

839

1,181

Current portion of long-term debt

-

392

Current portion of operating lease liability

1,846

849

Current portion of finance lease obligations

21

21

Total current liabilities

11,426

12,462


Operating lease liability, net of current portion

13,829

4,983

Finance lease obligations, net of current portion

-

26

Total liabilities

25,255

17,471


Commitments and contingencies


Shareholders' Equity

Common stock at par value

171

164

Additional paid-in capital

772,221

742,042

Accumulated other comprehensive loss

(127

)

(19

)

Accumulated deficit

(682,524

)

(629,433

)

Total shareholders' equity

89,741

112,754

Total liabilities and shareholders' equity

$

114,996

$

130,225


MicroVision, Inc.
Consolidated Statement of Operations
(In thousands, except per share data)
(Unaudited)


Three months ended December 31,

Twelve months ended December 31,


2022

2021

2022

2021

Product revenue

$

-

$

-

$

-

$

-

License and royalty revenue

-

557

664

2,500

Total revenue

-

557

664

2,500

Cost of product revenue

33

48

100

2

Total cost of revenue

33

48

100

2

Gross margin

(33

)

509

564

2,498

Research and development expense

7,585

6,482

30,413

24,111

Sales, marketing, general and administrative expense

6,377

6,648

24,041

22,256

Total operating expenses

13,962

13,130

54,454

46,367

Loss from operations

(13,995

)

(12,621

)

(53,890

)

(43,869

)

Gain on debt extinguishment

-

-

-

692

Other income (expense), net

520

(4

)

799

(23

)

Net income (loss)

$

(13,475

)

$

(12,625

)

$

(53,091

)

$

(43,200

)

Net income (loss) per share - basic and diluted

$

(0.08

)

$

(0.08

)

$

(0.32

)

$

(0.27

)

Weighted-average shares outstanding - basic and diluted

168,308

164,220

165,958

160,662


MicroVision, Inc.
Consolidated Statement of Cash Flows
(In thousands)
(Unaudited)

Twelve months ended December 31,


2022

2021

Cash flows from operating activities

Net loss

$

(53,091

)

$

(43,200

)

Adjustments to reconcile net loss to net cash used in operations:

Depreciation and amortization

2,246

1,464

Impairment of property and equipment

64

882

Share-based compensation expense

15,461

15,284

Non-cash interest expense

-

(10

)

Inventory write-downs

87

48

Net accretion of premium on short-term investments

21

86

Gain on debt extinguishment

-

(692

)

Change in

Inventory

(168

)

(1,828

)

Other current and non-current assets

(217

)

(2,552

)

Accounts payable

(1,737

)

2,520

Accrued liabilities

888

675

Contract liabilities and other current liabilities

(293

)

(1,319

)

Operating lease liabilities

(1,280

)

(762

)

Net cash used in operating activities

(38,019

)

(29,404

)


Cash flows from investing activities

Sales of investment securities

60,576

-

Purchases of investment securities

(90,158

)

(32,825

)

Advance to IBEO

(4,132

)

-

Purchases of property and equipment

(4,359

)

(2,493

)

Net cash provided by (used in) investing activities

(38,073

)

(35,318

)

Cash flows from financing activities

Principal payments under finance leases

(26

)

(28

)

Principal payments under long-term debt

(392

)

(488

)

Payments received on subscriptions receivable

-

6,135

Proceeds from stock option exercises

726

2,654

Net proceeds from issuance of common stock

13,999

122,891

Net cash provided by financing activities

14,307

131,164

Change in cash, cash equivalents, and restricted cash

(61,785

)

66,442

Cash, cash equivalents and restricted cash at beginning of period

83,739

17,297



Cash, cash equivalents and restricted cash at end of period

$

21,954

$

83,739


MicroVision, Inc.
Reconciliation of GAAP Net Loss to Non-GAAP Measure
(In thousands, except earnings per share data)
(Unaudited)


Three months ended December 31,

Twelve months ended December 31,


2022

2021

2022

2021

GAAP net loss

$

(13,475

)

$

(12,625

)

$

(53,091

)

$

(43,200

)

Add Interest (net)

(554

)

(2

)

(954

)

7

Add Income taxes

-

-

-

-

Add Depreciation & amorization

821

424

2,246

1,464

Add Share-based compensation expense

3,526

2,939

15,461

15,284

Adjusted EBITDA

$

(9,682

)

$

(9,264

)

$

(36,338

)

$

(26,445

)

Investor Relations Contact

Jeff Christensen
Darrow Associates Investor Relations
MVIS@darrowir.com

Media Contact

Robyn Komachi
Marketing@MicroVision.com

SOURCE: MicroVision, Inc.



View source version on accesswire.com:
https://www.accesswire.com/741236/MicroVision-Announces-Fourth-Quarter-and-Full-Year-2022-Results